GeoVax Presents Coronavirus Vaccine Data at European Society of Medicine
Aug 20, 2021 By MarketDepth
GeoVax Labs, Inc. (NASDAQ: GOVX) has presented data from its ongoing studies of its preventive vaccine to combat the coronavirus. “Design of a Universal SARS-CoV-2 Vaccine Against Evolving Variants,” was relayed virtually by Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer, during the European Society of Medicine (ESMED) General Assembly, that is held August 19-21 in Berlin, Germany. The development of the first generation SARS-CoV-2 vaccines have proven to be highly effective in the human population and designed to encode the stabilized Spike protein (S) with the goal of inducing high levels of neutralizing antibodies. Limitations of focusing on S are becoming more apparent with new variants that partially escape neutralization by vaccine induced antibodies.
Our studies to date support the use of MVA as a vector for the design and production of next-generation vaccines”Mark J. Newman, Ph.D., GeoVax’s Chief Scientific Officer
Dr. Newman commented, “Our studies to date support the use of MVA as a vector for the design and production of next-generation vaccines encoding multiple coronavirus proteins, using the S protein as the antibody target and the M and E proteins as T-cell targets. The combination of S, M and E protein expression supports VLP formation and optimal immunogenicity. In our studies, we observed the induction of functional antibodies and T-cell responses that mediate protection from infection and pathogenesis.”
Covid-19 Vaccine Results
David Dodd, GeoVax President and CEO, further commented, “The presentation of data from this study further validates our platform and approach to addressing COVID-19 and its variants. Our vaccines under development are intended to be used as either a primary vaccine or to boost other COVID-19 vaccines as part of vaccination strategies to provide immunity to a range of coronavirus variants. We believe a critical and significant opportunity exists for a pan-coronavirus vaccine with the attributes the GV-MVA-VLP™ technology can offer.”